1 Department of Pharmacy Practice, Annamalai University, Annamalai Nagar, Tamil Nadu, India

2 Department of Clinical, Social and Administrative Sciences, University of Michigan, Ann Arbor, MI, USA

3 Department of Public Health Sciences, The Pennsylvania State University, Pennsylvania, USA


Phamacoeconomics can aid the policy makers and the healthcare providers in decision making 
in evaluating the affordability of and access to rational drug use. Efficiency is a key concept 
of pharmacoeconomics, and various strategies are suggested for buying the greatest amount 
of benefits for a given resource use. Phamacoeconomic evaluation techniques such as cost 
minimization analysis, cost effectiveness analysis, cost benefit analysis, and cost utilization 
analysis, which support identification and quantification of cost of drugs, are conducted in a 
similar way, but vary in measurement of value of health benefits and outcomes. This article 
provides a brief overview about pharmacoeconomics, its utility with respect to the Indian 
pharmaceutical industry, and the expanding insurance system in India. Pharmacoeconomic 
evidences can be utilized to support decisions on licensing, pricing, reimbursement, and 
maintenance of formulary procedure of pharmaceuticals. For the insurance companies to 
give better facility at minimum cost, India must develop the platform for pharmacoeconomics 
with a validating methodology and appropriate training. The role of clinical pharmacists 
including PharmD graduates are expected to be more beneficial than the conventional 
pharmacists, as they will be able to apply the principles of economics in daily basis practice 
in community and hospital pharmacy.


1.Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. 
Natl Med J India 2004;17:80‑3.
2. Drummond MF, Sculpher MJ, Torrance GW. Critical 
Assessment of Economic Evaluation. Methods for the 
Economic Evaluation of Health Care Programmes. 3rd ed. 
Oxford: Oxford University Press; 2005.
3. MeiJen Ho, Joish NV, Biskupiak EJ. The role of 
pharmacoeconomics in formulary management: Triptan 
case study for migraine. Pharmacy and Therapeutics Journal. 
4. Bennett PN, Brown MJ. Topics in drug therapy. Clinical 
Pharmacology. 9th ed. Edinburgh: Churchill Livingstone; 2003. 
p. 24.
5. Bootman JL, Townsend RJ, McGhan WF. Introduction of 
Pharmacoeconomics. Principles of Pharmacoeconomics. 
2nd ed. Cincinnati OH: Harvey Whitney Books Co; 1996.
6. Jana S, Mondal P. Pharmacoeconomics: The need to sensitize 
undergraduate medical students. Indian J Pharmacol 
7. International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). Brief definition [online]. Available from: 
URL: [Last 
accessed on 2012 Feb 20].
8. Parthasarathi G, Nyfort‑Hansen K, Nahata MC. 
Pharmacoeconomics. A Textbook of Clinical Pharmacy 
Practice, Essential Concepts and Skills. Registered office 
3‑6‑752 Hymayat Nagar, Hyderabad‑500 029 (AP), India: 
Orient Longman Private Limited; 2007. p. 378.
9. McGhan WF, Rowland CR, Bootman JL. Cost‑benefit and 
cost‑effectiveness: Methodologies for evaluating innovative 
pharmaceutical services. Am J Hosp Pharm 1978;35:133‑40.
10. Bootman JL, Wertheimer AI, Zaske D, Rowland C. 
Individualizing gentamicin dosage regimens in burn patients 
with gram‑negative septicemia: A cost–benefit analysis. 
J Pharm Sci 1979;68:267‑72.
11. Rajesh B, Isha BP, Chang J. The Emerging role of 
pharmacoeconomics in the Indian scenario. Indian J. Pharm. 
Pract 2010;2:1‑5.
12. Bootman JL, Townsend RJ, McGham WF. Principles 
of Pharmacoeconomics, Chapter 1, Introduction to 
Pharmacoeconomics. Available from: http://www.hwbooks.
com/pharmacoeconomics3ed/chp1.pdf. [Last accessed on 
2012 Feb 20].
13. Draft national pharmaceuticals pricing policy, 2011(NPPP, 
2011). Available from:
mshT2810/FTY2.pdf. [Last accessed on 2012 Feb 20].
14. India’s 2011 Census, a population turning point. Available 
indias‑2011‑census‑a‑population‑turning‑point/. [Last 
accessed on 2012 Feb 20].
15. Goldstein H. Medical education in India does not address 
larger social needs for health care. Science and Environment 
Online. Available from: http://www.downtoearth.
cover [Last accessed on 2012 Feb 20].
16. LalPG. Report of the National Commission on Macroeconomics 
and Health. New Delhi: National Commission on 
Macroeconomics and Health, Ministry of Health and Family 
Welfare, Government of India; 2005. Available from http://
nrhm‑ [Last accessed on 
2012 Feb 20]
17. Confederation of Indian Industry. India Brand Equity 
Foundation News letter. 2010. Available from: http://www.ibef.
org/artdisplay.aspx?art_id=27385&cat_id=114&page=1 [Last 
accessed on 2012 Feb 20].
18. Jana S, Mondal P. Pharmacoeconomics: The need to sensitize 
undergraduate medical students. Indian J Pharmacol 
19. Guidelines for the Pharmaceutical Industry on Preparation 
of Submission to the Pharmaceutical Benefits Advisory 
Committee. Canberra: Australian Government Printing 
Service; 1992. Available from:
pharm/pubs/guidelines/content.htm.[Last accessed on 
2011 May 5].
20. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion 
of cost effectiveness in licensing requirements of new drugs: 
The fourth hurdle. BMJ 2004;329:972‑5.
21. Drug and Therapeutic Committees: A practical guide, 
managing the formulary process, WHO; 2003. Page No. 15‑21, 
Available from:
Js4882e/5.html. [Last accessed on 2012 May 5].
22. Sulger JF. A closer look at capitation. Am J Manag Care
23. TrudeS, AuM, ChristiansonJB. Health plan pay‑for‑performance 
strategies. Am J Manag Care 2006;12:537‑42.
24. Dixon A, Greene J, Hibbard J. Do consumer‑directed health 
plans drive change in enrollees’ health care behavior? Health 
Aff (Millwood) 2008;27:1120‑31.